PAPER Logue MW, Schu M, Vardarajan BN, Buros J, Green RC, Go RC, Griffith P, Obisesan TO, Shatz R, Borenstein A, Cupples LA, Lunetta KL, Fallin MD, Baldwin CT, Farrer LA,
SEARCH RESULTS
331942 RESULTS
PAPER Salvà A, Andrieu S, Fernandez E, Schiffrin EJ, Moulin J, Decarli B, Rojano-I-Luque X, Guigoz Y, Vellas B,
Health and nutrition promotion program for patients with dementia (NutriAlz): cluster randomized trial.
J Nutr Health Aging. 2011;15(10):822-30. PubMed: 22159768PAPER Nicholson AM, Wold LA, Walsh DM, Ferreira A
BETA-AMYLOID CARRYING THE DUTCH MUTATION HAS DIVERSE EFFECTS ON CALPAIN-MEDIATED TOXICITY IN HIPPOCAMPAL NEURONS.
Mol Med. 2011 Dec 1; PubMed: 22160219PAPER Launer LJ, Hughes TM, White LR
Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study.
Ann Neurol. 2011 Nov;70(5):774-80. PubMed: 22162060PAPER Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TL, Morris JC
Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data.
Ann Neurol. 2011 Nov;70(5):857-61. PubMed: 22162065PAPER Satler C, Tomaz C
Emotional working memory in Alzheimer's disease patients.
Dement Geriatr Cogn Dis Extra. 2011 Jan;1(1):124-38. PubMed: 22163239PAPER Komarova NL, Thalhauser CJ
Calculating stage duration statistics in multistage diseases.
PLoS One. 2011;6(12):e28298. PubMed: 22163291PAPER Zamani M, Mehri M, Kollaee A, Yenki P, Ghaffarpor M, Harirchian MH, Shahbazi M
Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients.
Dement Geriatr Cogn Dis Extra. 2011 Jan;1(1):180-9. PubMed: 22163243Vivekanandhan Viswanathan
India
PAPER Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC
The short test of mental status. Correlations with standardized psychometric testing.
Arch Neurol. 1991 Jul;48(7):725-8. PubMed: 1859300PAPER Boustani MA, Sachs GA, Alder CA, Munger S, Schubert CC, Guerriero Austrom M, Hake AM, Unverzagt FW, Farlow M, Matthews BR, Perkins AJ, Beck RA, Callahan CM
Implementing innovative models of dementia care: The Healthy Aging Brain Center.
Aging Ment Health. 2011 Jan;15(1):13-22. PubMed: 21271387PAPER Vickrey BG, Mittman BS, Connor KI, Pearson ML, Della Penna RD, Ganiats TG, DeMonte RW, Chodosh J, Cui X, Vassar S, Duan N, Lee M
The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial.
Ann Intern Med. 2006 Nov 21;145(10):713-26. PubMed: 17116916Bart De Strooper on Testing the right target and right drug at the right stage.
COMMENT The scientific evidence in favor of amyloid-β being part of the AD mechanism is, in my opinion, very clear. It is crucial that this hypothesis be fully tested in the clinic. The discussion on cause and consequence of amyloid is not entirely dissimilar to
Mary Donnelly
Takeda PharmaceuticalsDeerfield, United States
John Hardy on Testing the right target and right drug at the right stage.
COMMENT Sperling and colleagues cite three possible reasons why amyloid-targeted therapies may not yet have shown efficacy: 1) wrong mechanism, 2) right mechanism, but drug not hitting target, and 3) right mechanism, right target, but too late. That pretty much c
Current Filters
No filters selected